Horizon Pharma PLC (HZNP) Short Interest Down 10.2% in October
Horizon Pharma PLC (NASDAQ:HZNP) was the recipient of a large drop in short interest in October. As of October 13th, there was short interest totalling 14,756,238 shares, a drop of 10.2% from the September 29th total of 16,439,956 shares. Approximately 9.1% of the shares of the stock are sold short. Based on an average daily volume of 2,426,334 shares, the days-to-cover ratio is presently 6.1 days.
HZNP has been the topic of a number of research analyst reports. UBS AG set a $16.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a report on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a report on Monday, August 7th. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a report on Thursday, August 17th. BMO Capital Markets reaffirmed a “buy” rating and issued a $17.00 target price on shares of Horizon Pharma PLC in a report on Friday, July 28th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Horizon Pharma PLC in a report on Friday, July 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $18.00.
A number of large investors have recently made changes to their positions in HZNP. Prudential Financial Inc. grew its position in Horizon Pharma PLC by 2.6% in the first quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 420 shares in the last quarter. Wellington Management Group LLP purchased a new position in Horizon Pharma PLC in the first quarter worth $730,000. Massachusetts Financial Services Co. MA purchased a new position in Horizon Pharma PLC in the first quarter worth $151,000. Vanguard Group Inc. grew its position in Horizon Pharma PLC by 4.1% in the first quarter. Vanguard Group Inc. now owns 12,749,275 shares of the biopharmaceutical company’s stock worth $188,434,000 after acquiring an additional 506,596 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Horizon Pharma PLC by 0.7% in the first quarter. Geode Capital Management LLC now owns 1,379,581 shares of the biopharmaceutical company’s stock worth $20,389,000 after acquiring an additional 9,476 shares in the last quarter. Institutional investors own 82.55% of the company’s stock.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 13.56 on Wednesday. The firm’s market cap is $2.22 billion. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $21.98. The company’s 50 day moving average price is $13.19 and its 200 day moving average price is $12.61.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. During the same period in the previous year, the business earned $0.56 earnings per share. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. Equities research analysts forecast that Horizon Pharma PLC will post $1.07 EPS for the current year.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.